TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03626506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: After a 2-week run-in period on amlodipine, patients who still have SBP ≥ 140mmHg will take spironolactone 20mg once daily on top of amlodipine for 12 months. During the first two months after randomization, spironolactone can be titrated to 40mg if office SBP remains ≥ 140mmHg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indapamide
Description: After a 2-week run-in period on amlodipine, patients who still have SBP ≥ 140mmHg will take extended-release indapamide 1.5mg once daily on top of amlodipine for 12 months. During the first two months after randomization, indapamide can be titrated to 3mg if office SBP remains ≥ 140mmHg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: After a 2-week run-in period on amlodipine 5mg once daily, patients who still have SBP ≥ 140mmHg will be randomized to add spironolactone 20mg once daily or extended-release indapamide 1.5mg once daily to amlodipine for 12 months. During the first two months after randomization, amlodipine can be titrated to 10mg if office SBP remains ≥ 140mmHg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: After a 2-week run-in period on amlodipine 5mg once daily, patients who still have SBP ≥ 140mmHg will be randomized to add spironolactone 20mg once daily or extended-release indapamide 1.5mg once daily to amlodipine for 12 months. During the first two months after randomization, amlodipine can be titrated to 10mg if office SBP remains ≥ 140mmHg.
Study: NCT02140307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Response-based Mental Health Promotion (RR-MHP)
Description: The Open and Calm intervention is based on a standardized 9-week program. Week 1 uses a simple mantra-based meditation. Week 2 and 5 uses focus on the body. Week 3 and 6 uses focus on thoughts and emotions. Week 4 and 7 uses focus on social relationships. Weeks 8 and 9 were entitled The focus you feel like, where participants chose their own focus (e.g. two weeks of bodily focus if that was most relevant for a person, while another might chose 1 week focusing on emotions and another focusing on a social relationship).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Response-based Mental Health Promotion (RR-MHP)
Description: The Open and Calm intervention is based on a standardized 9-week program. Week 1 uses a simple mantra-based meditation. Week 2 and 5 uses focus on the body. Week 3 and 6 uses focus on thoughts and emotions. Week 4 and 7 uses focus on social relationships. Weeks 8 and 9 were entitled The focus you feel like, where participants chose their own focus (e.g. two weeks of bodily focus if that was most relevant for a person, while another might chose 1 week focusing on emotions and another focusing on a social relationship).
Study: NCT01560507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline (Chantix)
Description: For the first 3 days after being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion (Zyban)
Description: After being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive 150mg of bupropion once daily and 21mg nicotine patch for first 3 days; 150mg of bupropion twice daily and 21mg nicotine patch for 7 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine patches
Description: 21mg nicotine patch for first 11 weeks; 14mg nicotine patch for next 2 weeks; 7mg nicotine patch for final 2 weeks.
Study: NCT01842022

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Sucrose
Description: Sucrose sweetened meal will be given to each of four groups who differ in their glucose tolerance

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Sucrose
Description: Sucrose sweetened meal will be given to each of four groups who differ in their glucose tolerance

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Sucrose
Description: Sucrose sweetened meal will be given to each of four groups who differ in their glucose tolerance

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Sucrose
Description: Sucrose sweetened meal will be given to each of four groups who differ in their glucose tolerance

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Glucose
Description: Glucose sweetened meal will be given to each of four groups who differ in their glucose tolerance

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Glucose
Description: Glucose sweetened meal will be given to each of four groups who differ in their glucose tolerance
Study: NCT01560507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine patches
Description: 21mg nicotine patch for first 11 weeks; 14mg nicotine patch for next 2 weeks; 7mg nicotine patch for final 2 weeks.
Study: NCT02506608

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operation of sensorized hand prosthesis
Description: Four TIME-4H electrodes will be implanted in the median and ulnar of the amputees. The electrodes will be connected with the STIMEP electrical multichannel stimulator. The stimulator will be connected with one of the sensorized prostheses. Afferent and efferent signals will be elaborated and integrated by the ODROID software.~The amputees will be able to control the prostheses movement and receive a sensory feedback from the prosthesis sensors.~The use of the prosthesis during different tasks will be considered the intervention.
Study: NCT01842022

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Glucose
Description: Glucose sweetened meal will be given to each of four groups who differ in their glucose tolerance

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Glucose
Description: Glucose sweetened meal will be given to each of four groups who differ in their glucose tolerance
Study: NCT06557226

Intervention type: OTHER
Intervention: oral and nutritional examination
Description: Participants will receive a comprehensive oral examination, nutritional examination and will fill an oral health related quality of life questionnaire.
Study: NCT00674362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Two 200 mg subcutaneous injections at Week 0, Week 2, and Week 4 followed by 200 mg injections every 2 weeks until the last drug administration (Week 22)
Study: NCT01231750

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin
Description: 0.1% topical cream,4cm spread over 8cm x 15cm area on skin, one time, 45 minutes prior to exercise
Study: NCT00674362

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two 0.9% saline subcutaneous injections at Week 0, Week 2, and Week 4 followed by 0.9% saline injections every 2 weeks until the last drug administration (Week 22)
Study: NCT02738060

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Baked Milk
Description: The patients in case group will be received baked milk daily in the form of muffin(30 cc milk (equal to 1/3 of milk's proteins) heated in 350 F or 180 C for 30 mints) for 6 months. They will be visited weekly in the first month and every 2 weeks in other 5 months. At the end of the 6 months, the patients will undergo oral food challenge by 30 grams baked cheese in the form of pizza cheese. If the test will be negative, they will receive pizza cheese 4 or 7 days per week for other 6 months. The patients will be followed every 2 weeks during this period.~Skin prick test and serum IgE levels will be done at the beginning of the study, at 6 and 12 months. IgG4, being specific for milk allergens, will also measured at the beginning and at 12 months of the study.
Study: NCT01231750

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: cream, 4cm spread over 8cm x 15cm area of skin
Study: NCT03545191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant 25 mg
Description: Daridorexant will be administered as tablets, orally, once daily in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg
Description: Daridorexant will be administered as tablets, orally, once daily in the evening.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as tablets, orally, once daily in the evening.
Study: NCT00604903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant of Pressure sensor.
Description: Implant of an Remon ImPressure implantable pulmonary artery pressure sensor utilizing the corresponding delivering system.
Study: NCT03829358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum IS-10506
Description: Fermented milk containing probiotic Lactobacillus plantarum IS-10506 to be consumed once daily for three weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fermented milk containing placebo to be consumed once daily for three weeks.
Study: NCT03712956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caelyx®
Description: Caelyx® every two weeks for 8 courses
Study: NCT00875875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin 200 mg TID for 3 days OR Rifaximin 600 mg Daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin 200 mg TID for 3 days OR Rifaximin 600 mg Daily for 3 days
Study: NCT00920088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir
Description: DRV/RTV 600/100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Description: LPV/RTV 400/100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 3mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Dextromethorphan 30mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Description: Flurbiprofen 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761
Description: NNRTI under investigation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761
Description: NNRTI under investigation
Study: NCT01655524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASSUAGE Protocol
Description: 75 mg of aminophylline injected intravenously 90 seconds following the radioisotope injection in the setting of regadenoson nuclear stress test of the heart.
Study: NCT02593227

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose FRα vaccine
Description: 165ug per peptide ID injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose FRα vaccine
Description: 165ug per peptide ID injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV infusion over 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV infusion over 1 hour

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose FRα vaccine
Description: 500ug per peptide ID injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose FRα vaccine
Description: 500ug per peptide ID injection
Study: NCT01566019

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumoral biopsy
Description: Every enrolled patient undergoes tumoral biopsy
Study: NCT03421041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral Tablet
Description: Dexamethasone Oral Tablet，0.75mg/tablet
Study: NCT03716531

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IORT
Description: IORT works by delivering radiation therapy to the tumor while reducing the amount of healthy tissue exposed to the radiation therapy
Study: NCT01941888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study: NCT02699385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone
Description: Each participants will receive Domperidone 0.25 milligram per killogram (mg/kg) of body weight of oral suspension thrice daily for up to 7 days.
Study: NCT01941888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Target Controlled Infusion
Study: NCT01418716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facilitation
Description: Facilitation is a change management process. In the TRANSIT study, the change consist in implementing the TRANSIT program in primary care clinics. In the facilitation group, external facilitators accompany, support, and empower clinical teams so they quickly develop a sense of ownership regarding new clinical practices and sustainably implement them with lower costs. External facilitators offer counseling, coaching, and various tools to an internal facilitation team composed of clinicians of the clinical team to support their efforts in implementing change in their practices. Facilitation activities are structured in a cycle of 4 steps, the Plan-Do-Study-Act cycle (PDSA cycle).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive diffusion
Description: Clinical teams in primary care clinics implement the TRANSIT program without the help of facilitators.
Study: NCT03155737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-acupressure
Description: A training course will be offered to subjects in this group to train them to perform self-acupressure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Knee health education
Description: A course regarding knee health will be offered to the subjects in this group.
Study: NCT00892788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management
Description: Prize-based contingency management for weight loss

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: weight loss manual-guided individual therapy sessions
Description: once weekly counseling sessions with research staff

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss manual-guided individual therapy sessions
Description: once weekly counseling sessions with research staff
Study: NCT00795496

Intervention type: PROCEDURE
Intervention: Histamine provocation
Description: A dosimetric histamine challenge test in which the provocative dose of inhaled histamine producing a decrease of 15% in FEV1 is measured.

Intervention type: PROCEDURE
Intervention: Skin prick tests
Description: Skin prick testing will be performed for: birch, timothy, mugwort, alder, pine, cat, dog, horse, house dust mite, Cladosporium herbarum.

Intervention type: PROCEDURE
Intervention: Serum IgE blood testing
Description: One blood test to measure total serum IgE

Intervention type: PROCEDURE
Intervention: Mantoux-testing
Description: Tuberculin (2 TU) s.c. on the forearm. The test is read after 72 hours.
Study: NCT06240871

Intervention type: OTHER
Intervention: Pulmonary artery pressure measurements
Description: The investigators will compare noninvasive measurements of right sided pressure measurements with invasive RHC performed in 3 steps:at rest, with agitated saline and with agitated echo contrast, Optison. This was not a clinical trial and there were no intervention arms per se. All patients received agitated saline and echocardiographic contrast.
Study: NCT02363842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin IQ™ MCM Coverlet
Description: Test article is the Skin IQ™ MCM, a Class II 510k exempt product. It is an overlay coverlet indicated to be used in conjunction with a pressure redistribution surface in order to aid in the prevention and treatment of skin breakdown and pressure ulcers for patients who require microclimate management of the skin.
Study: NCT02699385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Each participants will receive placebo oral suspension thrice daily for up to 7 days.
Study: NCT04026594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: MBSR teaches mindfulness meditation and mindful yoga exercises to develop non-judgmental awareness of moment-to-moment experience. The intervention duration is 8 weeks, with weekly two and half hours sessions. It will be delivered according to the fundamental concepts and specific techniques provided in the MBSR manualized protocol by Kabat-Zinn. The program also includes 30-min daily homework exercises.~MBSR teaches four main mindfulness practices: (1) body scan, a process of moving attention through the body; (2) mindful movement, consisting of gentle yoga stretches to develop awareness of body in movement; (3) sitting meditation; and (4) walking meditation. Inquiry and didactic teaching is also a part of MBSR and allows for some detailed exploration of participants' experiences.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation group
Description: control group
Study: NCT01551355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Children-Multicomponent intervention
Description: The intervened children were provided classroom educational and playful activities during 5 months, which included Sesame Workshop Healthy Habits storybooks, posters, videos, games, and songs (1 hour daily); a Healthy family day workshop (1 hour); and weekly health notes. Parents participated in 3 workshops and weekly notes containing positive health messages about nutrition and active lifestyles to share with their children. Teachers also participated in 3 centralized training sessions, plus personalized working sessions with a research supervisor (2 hours every 15 days), and received a teacher's guide.
Study: NCT02024685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Treatment Recommendations
Description: This is a psychosocial/behavioral study. It will use a randomized trial to test the hypothesis that a decision analysis model that provides individualized estimates of quality-adjusted disease-free survival for each of the treatment options for clinically localized prostate cancer will lead to higher quality treatment decisions congruent with a patient's values leading to improved decisional regret and treatment satisfaction. In this trial, all patients would be evaluated at baseline for their utilities for various clinically important health states. The primary endpoint of this study will be regret-free survival at 2 years after treatment. There will be a 1:1 randomization. A random permuted design will be used to assure approximate balanced number of patients in the two groups over time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard patient-physician counseling interaction
Description: Both patients and physicians will be unaware of the decision analysis recommendation and the patients will receive standard treatment counseling alone. After the patient has made a treatment decision he will be given a short questionnaire to assess decisional conflict. If after one month no treatment decision information is available, a letter and form requesting treatment information along with the decisional conflict questionnaire will be sent to patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard patient-physician counseling interaction
Description: Both patients and physicians will be unaware of the decision analysis recommendation and the patients will receive standard treatment counseling alone. After the patient has made a treatment decision he will be given a short questionnaire to assess decisional conflict. If after one month no treatment decision information is available, a letter and form requesting treatment information along with the decisional conflict questionnaire will be sent to patients.
Study: NCT03876210

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: PK101
Description: PK101-001 + PK101-002 (combination)

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: PK101
Description: PK101-001 + PK101-002 (combination)

Intervention type: DRUG
Group type: OTHER
Intervention: PK101-001, PK101-002
Description: coadministration

Intervention type: DRUG
Group type: OTHER
Intervention: PK101-001, PK101-002
Description: coadministration
Study: NCT01976312

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham injections referred to the imitation of an intravitreal injection using an injection syringe without needle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Description: Ranibizumab solution for injection was supplied in vials. Each vial contained ranibizumab concentration of 10mg/mL labeled as 0.5 mg/0.5 mL, corresponding to a 0.5 mg dose level. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial for single use only
Study: NCT01524952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: combined thermal and electrical muscle stimulation (cTEMS)
Description: cTEMS in three 60-minute sessions per week for 8 weeks
Study: NCT02971085

Intervention type: PROCEDURE
Intervention: Active surveillance
Description: Active surveillance cohorts are routinely performed the systematic biopsy ≥ 12 cores by TRUS-guided or MR-TRUS fusion according to the protocol based by time path as 1, 2, 4, 7, 10 years and subsequently every 5 years following initial TRUS biopsy.
Study: NCT02738320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NHCPlus
Description: A decision-aid tool that will interface with Nursing Home Compare and improve consumers' ability to assimilate and incorporate the information into their process of choosing a nursing home.
Study: NCT01291381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dermatophagoides pteronyssinus
Description: Children undergoing subcutaneous immunotherapy were given Dermatophagoides pteronyssinus extract (Alutard SQ, ALK-Abello, Hørsholm, Denmark) according to a cluster protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacotherapy
Description: For patients randomized to non-SIT group, persistent rhinitis was managed with pharmacotherapy including intranasal steroids and oral antihistamines. Intranasal steroids were kept at the same dose during the study and antihistamines were used as required.
Study: NCT02163252

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard